Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Life Science Alliance(2022)10.26508/lsa.202101200Source: DataRank Database

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19 is a research paper published in Life Science Alliance (2022). On theSindex it has a DataRank of 1.2. It has been cited 52 times, with 38 citing works in its 1-hop citation network.

N/A

1.2DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access52 citations · 38 citing works in its network

Download PDF

Cite:

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT04382066

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (26 grants)OA: goldTopics (82)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 51%Citation Network 49%

Base Score Contribution

0.596

From this paper's citation signal

Citation Network Contribution

0.567

From 29 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 38 citers.

A Survey of Didemnin Depsipeptide Production in Tistrella
Marine Drugs202310 citations23 referencesContributes 0.104
Insights for COVID-19 in 2023
Revista Española de Quimioterapia202282 citations111 referencesContributes 0.040
Synthesis and Performance of l-Tryptophanamide and (S)-1-(Naphthalen-2′-yl)ethanamine-Based Marfey-Type Derivatives for Amino Acid Configurational Analysis: Diastereomeric Resolutions Directed by π–Cation Bonding
The Journal of Organic Chemistry20252 citations28 referencesContributes 0.039
Investigating the Structure-Activity Relationship of Marine Polycyclic Batzelladine Alkaloids as Promising Inhibitors for SARS-CoV-2 Main Protease (Mpro)
ChemRxiv20227 citations54 referencesContributes 0.039
Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
European Journal of Medicinal Chemistry Reports202224 citations97 referencesContributes 0.033

Authors (51)

Pedro Landete ORCID,José A. López-Martín ORCID,Vicente Estrada ORCID,Roger Paredes ORCID,Pablo Guisado‐Vasco ORCID

Live enrichment

PubMed:35012962

Government of Spain

Grant: PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043

National Institutes of Health

Grant: P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302

Excellence in Research Award

Grant: #133122P

Defense Advanced Research Projects Agency

Grant: #HR0011-19-2-0020

CRIPT, NIAID supported Center of Excellence for Influenza Research and Response

Grant: 75N93021C00014

DARPA

Grant: HR0011-19-2-0020

NIAID

Grant: U19AI142733, U19AI135972

DoD

Grant: W81XWH-20-1-0270

JPB Foundation, Open Philanthropy Project

Grant: 2020-215611 (5384)

National Institutes of Health

Grant: 5P01AI063302-03

Gene Expression Profiling Core

National Institutes of Health

Grant: 5R01AI120694-02

Discovery of novel, ubiquitin-regulated mechanisms of TB control by macrophages

National Institutes of Health

Grant: 3U19AI142733-04S1

Modulation of Lung Immune Responses to Viral Infection

Swiss National Science Foundation

Grant: 184202

Interaction of Myc-binding protein with the influenza A virus polymerase complex and its impact on viral fitness and host pathology

National Institutes of Health

Grant: 5U19AI135990-03

HPMI: Host Pathogen Mapping Initiative

National Institutes of Health

Grant: 5U19AI135972-04

Fluomics: The Next Generation

National Institutes of Health

Grant: 5P50AI150476-14

HARC Center: HIV Accessory and Regulatory Complexes

National Institutes of Health

Grant: 3R01AI143292-05S1

Novel VP30-host Interactions that Negatively Regulate Ebola Virus Infection

NIAID NIH HHS

Grant: U19 AI142733

Medical Research Council

Grant: MR/S023380/1

NIAID NIH HHS

Grant: U19 AI135990

NIAID NIH HHS

Grant: P01 AI063302

NIAID NIH HHS

Grant: P50 AI150476

NIAID NIH HHS

Grant: R01 AI143292

NIAID NIH HHS

Grant: R01 AI120694

Medical Research Council

Grant: MR/W005611/1

NIAID NIH HHS

Grant: U19 AI135972

goldLicense: cc-by

publisherhttps://www.life-science-alliance.org/content/lsa/5/4/e202101200.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.26508/lsa.202101200

repositoryhttps://ddd.uab.cat/record/252184

repositoryhttp://hdl.handle.net/10261/268634

repositoryhttps://doaj.org/article/18cda81fd9b149cb9c4f2bdcbbc8411b

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciencesAdultAgedCOVID-19Cell Line, TumorDepsipeptidesDrug Evaluation, PreclinicalFemaleHospitalizationHumansKaplan-Meier EstimateLength of StayMaleMiddle AgedNeutropeniaPeptides, CyclicSARS-CoV-2Treatment OutcomeViral LoadCOVID-19 Drug Treatment

MeSH Terms

AdultAgedCOVID-19Cell Line, TumorDepsipeptidesDrug Evaluation, PreclinicalFemaleHospitalizationHumansKaplan-Meier EstimateLength of StayMaleMiddle AgedNeutropeniaPeptides, CyclicSARS-CoV-2Treatment OutcomeViral LoadCOVID-19 Drug Treatment

Keywords

AdultMaleBiomedical and clinical sciencesNeutropeniaCoronavirusesClinical SciencesClinical Trials and Supportive ActivitiesDrug Evaluation, Preclinical610Kaplan-Meier EstimatePeptides, CyclicCell Line619Coronaviruses Therapeutics and InterventionsClinical ResearchCell Line, TumorDepsipeptidesHumansLungResearch ArticlesAgedCyclicTumorSARS-CoV-2COVID-19Length of StayMiddle AgedViral LoadPreclinicalCOVID-19 Drug TreatmentHospitalizationBiological sciencesInfectious DiseasesEmerging Infectious DiseasesGood Health and Well BeingTreatment Outcome6.1 PharmaceuticalsDrug EvaluationFemalePatient SafetyPeptides

Sustainable Development Goals

SDG 3: 3. Good health

Related Papers (1)

Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A

N/A

9.0DataRank · unranked

Science(2021)

co-cited

10.1126/science.abf4058